A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results.
Yanhong Deng(Sun Yat-sen University), Jianping Wang(Sun Yat-sen University), Long Cui(Jiangsu Normal University), Yue Cai(Sun Yat-sen University), Chen Daoda(Huazhong University of Science and Technology), Yiding Luo(First Affiliated Hospital of Xiamen University), Guangfu Cai(Guangdong Provincial People's Hospital), Jie Cao(Second Affiliated Hospital of Guangzhou Medical University), Hongbo Wei(Sun Yat-sen University), Pan Chi(Fujian Medical University), Lei Wang(Zhejiang Chinese Medical University), Ren Zhao(Shanghai Jiao Tong University), Ping Lan(Sun Yat-sen University), Yuxin Zhang, Xiang Peng, Zhongcheng Huang(Zhujiang Hospital), Zong-hai Huang(University of Electronic Science and Technology of China)
Cited by 20
Related Papers
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
|Journal of Clinical Oncology|2019|410
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
|Journal of Clinical Oncology|2016|409
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
|Nature|2017|402